Table 1.

Comparison of efficacy and safety profile between gemcitabine–nab-paclitaxel and FOLFIRINOX

 1-year survival35%48.4%
 Median OS8.5 mo.11.0 mo
 Median PFS5.5 mo.6.4 mo
Toxicity profile (grade 3 or worse)
 Febrile neutropenia3%5.4%
 Sensory neuropathy17%9%

NOTE: The gemcitabine-only control arms from MPACT and PRODIGE4/ACCORD11 were similar in efficacy and toxicity risks.

Abbreviations: mo, months; ORR, objective response rate; OS, overall survival; PFS, progression-free survival.

  • aMPACT (8).

  • bPRODIGE4/ACCORD11 (7).